Raptiva (efalizumab): Boxed Warning describes risk for life-threatening infections
Raptiva (efalizumab) Audience: Dermatological healthcare professionals, patients FDA notified healthcare professionals of extensive labeling changes, including a Boxed Warning, to
Read More